These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
339 related articles for article (PubMed ID: 32339565)
1. COVID-19 and cardiovascular disease: What we know, what we think we know, and what we need to know. Dhawan R; Gundry RL; Brett-Major DM; Mahr C; Thiele GM; Lindsey ML; Anderson DR J Mol Cell Cardiol; 2020 Jul; 144():12-14. PubMed ID: 32339565 [No Abstract] [Full Text] [Related]
2. The role of ACEIs/ARBs in COVID-19: Friend or foe? Zhou Z; Qiu Y; Tao J Med Hypotheses; 2020 Sep; 142():109810. PubMed ID: 32413701 [No Abstract] [Full Text] [Related]
3. Cardiovascular Pharmacology in the Time of COVID-19: A Focus on Angiotensin-Converting Enzyme 2. Buckley LF; Cheng JWM; Desai A J Cardiovasc Pharmacol; 2020 Jun; 75(6):526-529. PubMed ID: 32301766 [TBL] [Abstract][Full Text] [Related]
4. Coronavirus Disease 2019 (COVID-19): Do Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Have a Biphasic Effect? Sommerstein R; Kochen MM; Messerli FH; Gräni C J Am Heart Assoc; 2020 Apr; 9(7):e016509. PubMed ID: 32233753 [No Abstract] [Full Text] [Related]
5. Kidney and Lung ACE2 Expression after an ACE Inhibitor or an Ang II Receptor Blocker: Implications for COVID-19. Wysocki J; Lores E; Ye M; Soler MJ; Batlle D J Am Soc Nephrol; 2020 Sep; 31(9):1941-1943. PubMed ID: 32669323 [No Abstract] [Full Text] [Related]
6. Correlation between renin-angiotensin system and Severe Acute Respiratory Syndrome Coronavirus 2 infection: What do we know? Vitiello A; Ferrara F Eur J Pharmacol; 2020 Sep; 883():173373. PubMed ID: 32679185 [TBL] [Abstract][Full Text] [Related]
7. Clinical Implications of SARS-CoV-2 Interaction With Renin Angiotensin System: JACC Review Topic of the Week. Brojakowska A; Narula J; Shimony R; Bander J J Am Coll Cardiol; 2020 Jun; 75(24):3085-3095. PubMed ID: 32305401 [TBL] [Abstract][Full Text] [Related]
8. Drugs and the renin-angiotensin system in covid-19. Aronson JK; Ferner RE BMJ; 2020 Apr; 369():m1313. PubMed ID: 32241880 [No Abstract] [Full Text] [Related]
9. SARS-CoV-2 downregulation of ACE2 and pleiotropic effects of ACEIs/ARBs. Ciulla MM Hypertens Res; 2020 Sep; 43(9):985-986. PubMed ID: 32523133 [No Abstract] [Full Text] [Related]
10. A Meta-analysis of the Relationship Between Renin-Angiotensin-Aldosterone System Inhibitors and COVID-19. Usman MS; Siddiqi TJ; Khan MS; Ahmed A; Ali SS; Michos ED; Hall ME; Krasuski RA; Greene SJ; Butler J; Alkhouli M Am J Cardiol; 2020 Sep; 130():159-161. PubMed ID: 32624189 [No Abstract] [Full Text] [Related]
11. Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19. Vaduganathan M; Vardeny O; Michel T; McMurray JJV; Pfeffer MA; Solomon SD N Engl J Med; 2020 Apr; 382(17):1653-1659. PubMed ID: 32227760 [No Abstract] [Full Text] [Related]
12. Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19. Diaz JH J Travel Med; 2020 May; 27(3):. PubMed ID: 32186711 [TBL] [Abstract][Full Text] [Related]
13. Cardiovascular disease and the impact of COVID-19. Yoganathan A; Sajjad MS; Harky A J Card Surg; 2020 Aug; 35(8):2113. PubMed ID: 32542799 [No Abstract] [Full Text] [Related]
14. SARS-CoV-2 receptor ACE2-dependent implications on the cardiovascular system: From basic science to clinical implications. Groß S; Jahn C; Cushman S; Bär C; Thum T J Mol Cell Cardiol; 2020 Jul; 144():47-53. PubMed ID: 32360703 [TBL] [Abstract][Full Text] [Related]
15. Potential harmful effects of discontinuing ACE-inhibitors and ARBs in COVID-19 patients. Rossi GP; Sanga V; Barton M Elife; 2020 Apr; 9():. PubMed ID: 32250244 [TBL] [Abstract][Full Text] [Related]
16. Renin-angiotensin system and SARS-CoV-2 interaction: underlying mechanisms and potential clinical implications. Hrenak J; Zorad S; Simko F Gen Physiol Biophys; 2020 May; 39(3):203-204. PubMed ID: 32525813 [TBL] [Abstract][Full Text] [Related]
18. Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors-lessons from available evidence and insights into COVID-19. Kai H; Kai M Hypertens Res; 2020 Jul; 43(7):648-654. PubMed ID: 32341442 [TBL] [Abstract][Full Text] [Related]
19. ACEI/ARB therapy in COVID-19: the double-edged sword of ACE2 and SARS-CoV-2 viral docking. Onweni CL; Zhang YS; Caulfield T; Hopkins CE; Fairweather L; Freeman WD Crit Care; 2020 Jul; 24(1):475. PubMed ID: 32736573 [No Abstract] [Full Text] [Related]
20. The interplay of hypertension, ACE-2 and SARS-CoV-2: Emerging data as the "Ariadne's thread" for the "labyrinth" of COVID-19. Tsioufis C; Dimitriadis K; Tousoulis D Hellenic J Cardiol; 2020; 61(1):31-33. PubMed ID: 32450334 [No Abstract] [Full Text] [Related] [Next] [New Search]